-
Immunity | Sun Beicheng/Lin Anning collaborates to reveal a new mechanism of liver cancer transformation regulation
Time of Update: 2021-06-01
Lin Anning, a dual-appointed professor at Nanjing University Institute of Modern Biology and Drum Tower Hospital (Drum Tower Hospital, Nanjing University School of Medicine, Deputy Chief Physician Zhang Wenjie, PhD student Zhang Yuan Guangyan and Wang Fei as the first authors) published an article The zinc finger protein Miz1 suppresses liver tumorigenesis by restricting hepatocyte-driven macrophage activation and inflammation in Immunity, revealing a new mechanism for the regulation of liver cancer transformation.
-
Zhejiang Medicine's HER2-ADC drug is included in the list of breakthrough treatments for second-line treatment of HER2-positive advanced breast cancer
Time of Update: 2021-06-01
According to the latest announcement by the State Drug Administration, the recombinant humanized anti-HER2 monoclonal antibody-AS269 conjugate (ARX788) for injection developed by Zhejiang Pharmaceutical's subsidiary Xinma Biotechnology has ended its announcement on May 25 and officially included in the breakthrough treatment.
-
The third bispecific antibody has been approved by the FDA. Is there an outbreak in the field of dual antibodies?
Time of Update: 2021-06-01
Last week, the US FDA accelerated the approval of the bispecific antibody Rybrevant (amivantamab-vmjw) developed by Johnson & Johnson's Janssen Company for the treatment of EGFR exon 20 Patients with non-small cell lung cancer (NSCLC) with insertion mutations.
-
Express | KRAS mutation patients have a remission rate of 70%, and innovative RAF/MEK inhibitors are recognized as breakthrough therapy
Time of Update: 2021-06-01
▎Editor of WuXi AppTec Content Team On May 21, 2021, Verastam Oncology announced that its innovative small molecule RAF/MEK inhibitor VS-6766 has been granted a breakthrough therapy designation by the US FDA and combined with the specific FAK inhibitor defactinib to treat relapses Low-grade serous ovarian cancer (LGSOC).
-
Leukemia: Pomalidomide, dexamethasone, and darrimumab in the treatment of refractory multiple myeloma that relapsed after lenalidomide treatment
Time of Update: 2021-06-01
In the Phase 2 MM-014 study, researchers evaluated patients with relapsed or refractory multiple myeloma ( RRMM ) who were resistant to lenalidomide treatment , and evaluated pomalidomide , low-dose dexamethasone and The safety and efficacy of daratumumab, the results of the study have been published in Leukemia .
-
Express | Innovative ADC preliminary clinical trial results are positive, and the overall remission rate of Hodgkin's lymphoma patients can reach 86%
Time of Update: 2021-06-01
▎The content team editor of WuXi AppTec today, ADC Therapeutics announced its new antibody conjugate drug (ADC) camidanlumab tesirine (Cami) targeting CD25 for the treatment of relapsed/refractory Hodgkin and non-Hodgkin’s lymphoma The patient's Phase 1 clinical trial results were published on The Lancet Haematology.
-
Sub-Journal of "Nature": The first long-term smoking cessation of non-small cell lung cancer patients with prognosis-related multi-level molecular research results released, revealing that TNS3 and SEPT7 are related to prognosis
Time of Update: 2021-06-01
This multi-omics study based on genome, epigenome, transcriptome, and proteome reveals that TNS3 and SEPT7 are related to the prognosis of long-term (>10 years) smoking cessation lung cancer patients at different molecular levels.
-
2021 ASCO | CStone's selective RET inhibitor pratinib demonstrates long-lasting clinical activity in patients with metastatic RET fusion non-small cell lung cancer and advanced solid tumors
Time of Update: 2021-06-01
The results of the study show that pratinib has brought lasting clinical benefits to patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and other advanced solid tumors.
-
Deeply understand the continuous treatment of multiple myeloma, the most important points are here | MM continuous treatment series
Time of Update: 2021-06-01
In view of the heterogeneity of MM, continuous treatment strategies may need to include multiple drugs with different mechanisms of action to extend specific patient subgroups Disease control time tolerance/safety•Must be tolerable for a long period of time, with almost no cumulative or chronic toxicity, and no serious impact on the patient’s quality of life.
-
2021 ASCO | A quick overview of the research progress of lung cancer
Time of Update: 2021-06-01
3. New progress in EGFR resistance, HER3-targeted antibody conjugated drug (ADC) patritumab deruxtecan (U3-1402) after the line treatment of EGFR-TKI-resistant NSCLC patients, the DCR is 72% (Abstr 9007) will soon be at this meeting In the published phase I study of dose escalation/cohort expansion, 53 patients with locally advanced or metastatic NSCLC with EGFR mutations who had previously received EGFR-TKI treatment were included, and the median number of treatment lines was 4.
-
ASCO first look at the blockbuster|Reduce the risk of death by nearly 50%!
Time of Update: 2021-06-01
ASCO official website announced the results of KEYNOTE-590 Chinese population data analysis 1KEYNOTE-590 is a global multi-center, randomized, double-blind, phase III clinical study aimed at evaluating pembrolizumab (commonly known as “K drug” in China) combined with cis Platinum and 5-fluorouracil (5-FU), compared with the efficacy and safety of cisplatin and 5-FU in the first-line treatment of unresectable locally advanced or metastatic esophageal cancer.
-
2021 ASCO|Overcoming CAR-T resistance and tumor recurrence, Sibiman announces the latest data of two CAR-T pipelines
Time of Update: 2021-06-01
In the latest ASCO abstract, it shows good efficacy and safety, which is expected to bring new hope to patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
ASCO 2021 abstract published the clinical data of C-CAR039 to evaluate the safety and effectiveness of C-CAR039 in patients with relapsed/refractory B-NHL.
-
Cancer Cell Review: Cancer "Personality" Testing Helps Clinical Decision-making | Cell Press Express Articles
Time of Update: 2021-06-01
These cell interactions occur between immune cells and mesenchymal cells, and they are conservative among different tumor types.
In order to better guide treatment decisions, the authors also developed a visualization tool for tumor personality detection based on these findings.
-
Br J Haematol: Targeted capture sequencing for genomic analysis of multiple myeloma
Time of Update: 2021-06-01
The purpose of this study is to clarify the correlation between genomic abnormalities and clinical features through targeted capture sequencing in the Japanese multiple myeloma cohort.
gov/32386081/" target="_blank" rel="noopener">Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohort .
-
China's liver cancer clinical research is expected to achieve new breakthroughs-an opportunity brought by the era of "big integration" in liver cancer treatment
Time of Update: 2021-06-01
Recently, the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology (ASCO), published online the 50 most cited articles published in the journal during
-
Bone Res | Significant progress!
Time of Update: 2021-06-01
This research It shows that loading high levels of tyrosine hydroxylase (a rate-limiting enzyme in dopamine synthesis) in the tibia can significantly reduce the progression of brain tumors.
-
New options for advanced breast cancer treatment, Chinese innovative drug research shines on the international stage | ASCO 2021
Time of Update: 2021-06-01
This randomized, double-blind, phase 3 trial showed that in HR+/HER2-advanced breast cancer that recurred or progressed after endocrine therapy, dalpiciclib combined with fulvestrant can be significantly better than placebo combined with fulvestrant Improve progression-free survival (PFS) with controllable safety.
-
Strike again!
Time of Update: 2021-06-01
The company focuses on the development of world-leading breakthrough First-in-class and Best-in-class CAR-T cell drugs to benefit cancer patients.
-
TG Therapeutics' third-generation CD20 monoclonal antibody listing application was accepted by the U.S. FDA | Yimai Meng broke the news
Time of Update: 2021-06-01
Recent popular reports from Yimaike ★ Invitation to the event 2021 Oncolytic Virus Drug Development Forum is about to open in Shanghai ★ The financing has reached hundreds of millions in half a year,
-
Lancet Sub-Journal: Long-term colorectal cancer screening has significantly reduced related mortality|Tumor News
Time of Update: 2021-06-01
JTO: Sintilimab combined with platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small cells Lung cancer 01 The Lancet Oncol: Long-term screening for colorectal cancer, the related mortality rate has dropped significantly.
